Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany

Table 8 National Paediatric Rheumatological Database (NPRD) with a uveitis add-on module in Germany (2002–2016). Follow-up uveitis documentation: anti-inflammatory treatment in previous 12 months. Data as provided in NPDR and/or uveitis documentation

Follow-up documentation. Anti-inflammatory treatment in previous 12 months	Group I. Uveitis, ANA-positive, no JIA, N = 56		Group II. Uveitis manifestation after JIA disease onset*, N = 56		Group III. Uveitis manifestation before JIA disease onset*, N = 37		p value^†	Significant pairwise comparisons^‡
	Treatment	Uveitis inactivity^‡‡	Treatment*	Uveitis inactivity^‡‡	Treatment	Uveitis inactivity^‡‡
Any DMARD, n (%)	29 (53.7%)	13 (61.9%)	27 (49.1%)	5 (45.5%)	23 (63.9%)	6 (66.7%)	0.379
Methotrexate, n (%)	25 (46.3%)	11 (61.1%)	26 (47.3%)	5 (50.0%)	23 (63.9%)	6 (66.7%)	0.204
Adalimumab, n (%)	5 (12.2%)	3 (60.0%)	4 (12.9%)	2 (66.7%)	2 (9.5%)	0 (0.0%)	0.805
Systemic corticosteroids, n (%)	16 (32.7%)	6 (54.6%)	7 (13.2%)	1 (100.0%)	12 (35.3%)	2 (50.0%)	0.044	II vs. III
Topical corticosteroids, n (%)	33 (62.3%)	13 (54.2%)	29 (59.2%)	8 (50.0%)	24 (70.6%)	2 (28.6%)	0.446

^†Group effect for the proportion of treated patients by chi-squared test for categorical variables
^‡Pairwise comparisons for the proportion of treated patients with correction for multiple comparisons by Bonferroni (chi-squared test)
^‡‡Group I: n = 34; Group II: n = 27; Group III: n = 13 patients with documented AC cell count
*Initial uveitis diagnosis

ISSN: 1478-6362